Hypoxic tumor microenvironment in advanced retinoblastoma

Pediatric Blood and Cancer

Volumn 60, Issue 10, 2013, Pages 1598-1601

  Sudhakar, Job ^a,b   Venkatesan, Nalini ^a,b   Lakshmanan, Shruthi ^a   Khetan, Vikas ^b   Krishnakumar, Subramanian ^a   Biswas, Jyotirmay ^a  

^a VISION RESEARCH FOUNDATION   (India)

^b BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

Author keywords

CA IX; Chemoresistance; HIF 1; Hypoxia; Retinoblastoma; Survivin

Indexed keywords

CARBONATE DEHYDRATASE IX; HYPOXIA INDUCIBLE FACTOR 1ALPHA; SURVIVIN;

ADVANCED CANCER; ARTICLE; CELL HYPOXIA; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINOBLASTOMA; TUMOR DIFFERENTIATION; TUMOR INVASION; TUMOR MICROENVIRONMENT;

CA IX; CHEMORESISTANCE; HIF-1; HYPOXIA; RETINOBLASTOMA; SURVIVIN;

ANTIGENS, NEOPLASM; CARBONIC ANHYDRASES; CELL HYPOXIA; CHILD, PRESCHOOL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INHIBITOR OF APOPTOSIS PROTEINS; MALE; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; RETINOBLASTOMA; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT;

EID: 84881530284     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24599     Document Type: Article

References (42)

1. Kim JW, Abramson DH, Dunkel IJ. Current management strategies for intraocular retinoblastoma. Drugs 2007; 67:2173-2185.
2. Trédan O, Galmarini CM, Patel K, et al. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 2007; 99:441-454.
3. Kondoh E, Mori S, Yamaguchi K, et al. Targeting slow-proliferating ovarian cancer cells. Int J Cancer 2010; 15:2448-2456.
4. Rohwer N, Cramer T. Hypoxia-mediated drug resistance: Novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Update 2011; 1:191-201.
5. Harris AL. Hypoxia-a key regulatory factor in tumor growth. Nat Rev Cancer 2002; 2:38-47.
6. Zhong H, De Marzo AM, Laughner E, et al. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res 1999; 59:5830-5835.
7. O'Donnell JL, Joyce MR, Shannon AM. et al. Oncological implications of hypoxia inducible factor-1alpha (HIF-1alpha) expression. Cancer Treat Rev 2006; 32:407-416.
8. Wykoff CC, Beasley NJ, Watson PH, et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 2000; 60:7075-7083.
9. Bui MH, Seligson D, Han KR, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: Implications for prognosis and therapy. Clin Cancer Res 2003; 9:802-811.
10. Stillebroer AB, Peter FA. Carbonic anhydrase Ix in renal cell carcinoma: Implications for prognosis, diagnosis and therapy. Eur Urol 2010; 58:75-83.
11. Trastour C, Benizri E, Ettore F. HIF-1alpha and CA IX staining in invasive breast carcinomas: Prognosis and treatment outcome. Int J Cancer 2007; 120:1451-1458.
12. Tan EY, Yan M, Campo L, et al. The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumors and is associated with resistance to chemotherapy. Br J Cancer 2009; 100:405-411.
13. Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998; 396:580-584.
14. Taran J, Master Z, Yu JI, et al. A role of survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci 2002; 99:4345-4349.
15. Rodel C, Hass J, Groth A, et al. Spontaneous and radiation induced apoptosis in colorectal carcinoma cells with different intrinsic radiosensitivities: Survivin as a radioresistance factor. Int J Radiat Oncol Biol Phys 2003; 55:1341-1347.
16. Haberler C, Slavc I, Czech T, et al. Histopathological prognostic factors in medulloblastoma: High expression of survivin is related to unfavorable outcome. Eur J Cancer 2006; 42:2996-3003.
17. Sohn DM, Kim SY, Baek MJ, et al. Expression of survivin and clinical correlation in patients with breast cancer. Biomed Pharmacother 2006; 60:289-292.
18. Rootman J, Gallie B, Kumi C, et al. Ocular penetration, toxicity, and radiosensitization effects of two hypoxic cell radiosensitizers on retinoblastoma. Arch Ophthalmol 1986; 104:1693-1697.
19. Boutrid H, Piña Y, Cebulla CM, et al. Increased hypoxia following vessel targeting in a murine model of retinoblastoma. Invest Ophthalmol Vis Sci 2009; 50:5537-5543.
20. Houston SK, Piña Y, Murray TG, et al. Novel retinoblastoma treatment avoids chemotherapy: The effect of optimally timed combination therapy with angiogenic and glycolytic inhibitors on LH(BETA)T(AG) retinoblastoma tumors. Clin Ophthalmol 2011; 27:129-137.
21. Kaliki S, Shields CL, Rojanaporn D, et al. High-risk retinoblastoma based on international classification of retinoblastoma: analysis of 519 enucleated eyes. Ophthalmology 2013; 120:997-1003.
22. Eagle RC, Jr. High-risk features and tumor differentiation in retinoblastoma: A retrospective histopathologic study. Arch Pathol Lab Med 2009; 133:1203-1209.
23. Shi S-R, Chaiwun B, Young L, et al. Antigen retrieval technique utilizing citrate buffer or urea solution for immunohistochemical demonstration of androgen receptor in formalin-fixed paraffin sections. J Histochem Cytochem 1993; 41:1599-1604.
24. Hurks HM, Metzelaar-Blok JA, Barthen ER, et al. Expression of epidermal growth factor receptor: Risk factor in uveal melanoma. Invest Ophthalmol Vis Sci 2000; 41:2023-2027.
25. Mohan A, Kandalam M, Ramkumar HL, et al. Stem cell markers: ABCG2 and MCM2 expression in retinoblastoma. Br J Ophthalmol 2006; 90:889-893.
26. Detre S, Saclani Jotti G, Dowsett MA, Quickscore method for immunohistochemical semiquantitation: Validation for oestrogen receptor in breast carcinomas. J Clin Pathol 1995; 48:876-878.
27. Kim SJ, Rabbani ZN, Dewhirst MW, et al. Expression of HIF-1alpha, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer. Lung Cancer 2005; 49:325-335.
28. Peng XH, Karna P, O'Regan RM, et al. Down-regulation of inhibitor of apoptosis proteins by deguelin selectively induces apoptosis in breast cancer cells. Mol Pharmacol 2007; 71:101-111.
29. Ferrario A, Rucker N, Wong S, et al. Survivin, a member of the inhibitor of apoptosis family is induced by photodynamic therapy and is a target for improving treatment response. Cancer Res 2007; 67:4989-4995.
30. Jiang LB, Liu XQ, Li B, et al. Heat shock proteins and survivin: Relationship and effects on proliferation index of retinoblastoma cells. Histol Histopathol 2008; 23:827-831.
31. Fan LF, Dong WG, Jiang CQ, et al. Role of hypoxia-inducible factor-1 alpha and survivin in colorectal carcinoma progression. Int J Colorectal Dis 2008; 23:1057-1064.
32. Linn Murphree A. Intraocular retinoblastoma: The case for a new group classification. Ophthalmol Clin North Am 2005; 18:41-53.
33. Kashyap S, Sethi S, Meel R, et al. A histopathologic analysis of eyes primarily enucleated for advanced intraocular retinoblastoma from a developing country. Arch Pathol Lab Med 2012; 136:190-193.
34. Park E, Gang EJ, Hsieh YT, et al. Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia. Blood 2011; 118:2191-2199.
35. Morrison DJ, Hogan LE, Condos G, et al. Endogenous knockdown of survivin improves chemotherapeutic response in ALL models. Leukemia 2012; 26:271-279.
36. Shen J, Yin Q, Chen L, et al. Co-delivery of paclitaxel and survivin shRNA by pluronic P85-PEI/TPGS complex nanoparticles to overcome drug resistance in lung cancer. Biomaterials 2012; 33:8613-8624.
37. Sapra P, Wang M, Bandaru R, et al. Down-modulation of survivin expression and inhibition of tumor growth in vivo by EZN-3042 a locked nucleic acid antisense oligonucleotide. Nucleosides Nucleotides Nucleic Acids 2010; 29:97-112.
38. Estève PO, Chin HG, Pradhan S, et al. Molecular mechanisms of transactivation and doxorubicin-mediated repression of survivin gene in cancer cells. J Biol Chem 2007; 282:2615-2625.
39. Kelly RJ, Lopez-Chavez A, Citrin D, et al. Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin. Mol Cancer 2011; 10:35.
40. Ling X, Cao S, Cheng Q, et al. A Novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner shows superior antitumor activity. PLoS ONE 2012; 7:e45571.
41. Weiss A, Brill B, Borghouts C, et al. Survivin inhibition by an interacting recombinant peptide, derived from the human ferritin heavy chain, impedes tumor cell growth. J Cancer Res Clin Oncol 2012; 138:1205-1220.
42. McDonald PC, Winum JY, Supuran CT, et al. Recent developments in targeting carbonic anhydrase IX for cancer therapeutics. Oncotarget 2012; 3:84-97.